Semnur Pharmaceuticals, Inc. (SMNR)
| Market Cap | 137.90M -97.5% |
| Revenue (ttm) | n/a |
| Net Income | -167.68M |
| EPS | -0.76 |
| Shares Out | 230.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,765 |
| Open | 0.1279 |
| Previous Close | 0.4625 |
| Day's Range | 0.1279 - 0.6150 |
| 52-Week Range | 0.2500 - 23.0000 |
| Beta | -0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About Semnur Pharmaceuticals
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company. [Read more]
Financial Performance
Financial StatementsNews
Scilex approves dividend of Semnur Pharmaceuticals shares
Scilex (SCLX) announced that its board of directors approved a dividend of Semnur Pharmaceuticals (SMNR) common stock held by the company to its stockholders and certain other eligible equityholders o...